Article
Analysis of resistance-associated substitutions in acute hepatitis C virus infection by deep sequencing across six genotypes and three continents.
Journal of viral hepatitis - 1 Jan 2017
Eltahla A A, Rodrigo C, Betz-Stablein B, Grebely J, Applegate T, Luciani F, Schinkel J, Dore G J, Page K, Bruneau J, Morris M D, Cox A L, Kim A Y, Shoukry N H, Lauer G M, Maher L, Hellard M, Prins M, Lloyd A R, Bull R A
Abstract excerpt
Several direct-acting antivirals (DAAs) have been approved for the treatment of chronic hepatitis C virus (HCV) infections, opening the door to highly effective interferon-free treatment regimens. Resistance-associated substitutions (RASs) have been reported both in treatment-naïve patients and following treatment with protease (NS3), phosphoprotein (NS5A) and polymerase (NS5B) inhibitors. The prevalence of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
